Adacel® is only indicated for patients 10-64 years of age.2
BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diptheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals 10 years of age and older.
Severe allergic reaction after a previous dose of any tetanus toxoid-, diptheria toxoid-, or pertussis is antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine, is a contraindication.
Stock one Tdap* vaccine for all your eligible patients.
BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diptheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals 10 years of age and older.
Severe allergic reaction after a previous dose of any tetanus toxoid-, diptheria toxoid-, or pertussis antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine, is a contraindication.
- *Tetanus, diptheria, and acellular pertussis.
- †U.S. Food and Drug Administration
- Adacel is a registered trademark of Sanofi Pasteur group, and its subsidiaries.
- Trademarks are owned by or licensed to the GSK group of companies
Indication for BOOSTRIX
BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals 10 years of age and older.
Important Safety Information for BOOSTRIX
- Severe allergic reaction after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication
- The tip caps of the prefilled syringes for BOOSTRIX contain natural rubber latex, which may cause allergic reactions
- The decision to give BOOSTRIX should be based on benefits and risks if Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior tetanus toxoid-containing vaccine
- Syncope (fainting) can occur in association with administration of injectable vaccines. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- Progressive or unstable neurologic conditions are reasons to defer vaccination with a pertussis-containing vaccine, including BOOSTRIX
- Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of tetanus toxoid-containing vaccine should not receive BOOSTRIX unless 10 years have elapsed since the last dose of a tetanus toxoid-containing vaccine
- In clinical studies, common adverse reactions were pain, redness, and swelling at the injection site, increase in arm circumference of injected arm, headache, fatigue, gastrointestinal symptoms, and fever
- Vaccination with BOOSTRIX may not result in protection in all vaccine recipients
References
825072R0 October 2017